HC Wainwright Reaffirms “Buy” Rating for Rockwell Medical (NASDAQ:RMTI)

Rockwell Medical (NASDAQ:RMTI)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $2.50 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 117.39% from the company’s current price. HC Wainwright also issued estimates for Rockwell Medical’s Q4 2026 earnings at $0.01 EPS.

RMTI has been the topic of a number of other research reports. Wall Street Zen downgraded shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rockwell Medical in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $2.50.

Rockwell Medical Trading Up 5.5%

Rockwell Medical stock opened at $1.15 on Monday. Rockwell Medical has a one year low of $0.78 and a one year high of $2.15. The business’s fifty day moving average is $0.94 and its 200 day moving average is $1.11. The stock has a market capitalization of $45.31 million, a PE ratio of -7.19 and a beta of 1.65. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.91 and a quick ratio of 3.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Panagora Asset Management Inc. bought a new stake in Rockwell Medical in the second quarter worth $41,000. GSA Capital Partners LLP lifted its holdings in shares of Rockwell Medical by 635.1% in the 3rd quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock worth $197,000 after acquiring an additional 141,672 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Rockwell Medical by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock worth $1,625,000 after acquiring an additional 148,737 shares during the last quarter. 23.31% of the stock is currently owned by institutional investors.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.